ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review
Despite the protracted battle against coronavirus acute respiratory infection (COVID-19) and the rapid evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), no specific and effective drugs have to date been reported. Angiotensin-converting enzyme 2 (ACE2) is a zinc metallopr...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f3eb507a47094bab8b3cde90601693e3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f3eb507a47094bab8b3cde90601693e3 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f3eb507a47094bab8b3cde90601693e32021-11-11T16:56:43ZACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review10.3390/ijms2221114831422-00671661-6596https://doaj.org/article/f3eb507a47094bab8b3cde90601693e32021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11483https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Despite the protracted battle against coronavirus acute respiratory infection (COVID-19) and the rapid evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), no specific and effective drugs have to date been reported. Angiotensin-converting enzyme 2 (ACE2) is a zinc metalloproteinase and a critical modulator of the renin-angiotensin system (RAS). In addition, ACE2 has anti-inflammatory and antifibrosis functions. ACE has become widely known in the past decade as it has been identified as the primary receptor for SARS-CoV and SARS-CoV-2, being closely associated with their infection. SARS-CoV-2 primarily targets the lung, which induces a cytokine storm by infecting alveolar cells, resulting in tissue damage and eventually severe acute respiratory syndrome. In the lung, innate immunity acts as a critical line of defense against pathogens, including SARS-CoV-2. This review aims to summarize the regulation of ACE2, and lung host cells resist SARS-CoV-2 invasion by activating innate immunity response. Finally, we discuss ACE2 as a therapeutic target, providing reference and enlightenment for the clinical treatment of COVID-19.Lihua QuChao ChenTong YinQian FangZizhan HongRui ZhouHongbin TangHuifen DongMDPI AGarticleACE2immune cellsCOVID-19SARS-CoV-2ALIBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11483, p 11483 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
ACE2 immune cells COVID-19 SARS-CoV-2 ALI Biology (General) QH301-705.5 Chemistry QD1-999 |
| spellingShingle |
ACE2 immune cells COVID-19 SARS-CoV-2 ALI Biology (General) QH301-705.5 Chemistry QD1-999 Lihua Qu Chao Chen Tong Yin Qian Fang Zizhan Hong Rui Zhou Hongbin Tang Huifen Dong ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review |
| description |
Despite the protracted battle against coronavirus acute respiratory infection (COVID-19) and the rapid evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), no specific and effective drugs have to date been reported. Angiotensin-converting enzyme 2 (ACE2) is a zinc metalloproteinase and a critical modulator of the renin-angiotensin system (RAS). In addition, ACE2 has anti-inflammatory and antifibrosis functions. ACE has become widely known in the past decade as it has been identified as the primary receptor for SARS-CoV and SARS-CoV-2, being closely associated with their infection. SARS-CoV-2 primarily targets the lung, which induces a cytokine storm by infecting alveolar cells, resulting in tissue damage and eventually severe acute respiratory syndrome. In the lung, innate immunity acts as a critical line of defense against pathogens, including SARS-CoV-2. This review aims to summarize the regulation of ACE2, and lung host cells resist SARS-CoV-2 invasion by activating innate immunity response. Finally, we discuss ACE2 as a therapeutic target, providing reference and enlightenment for the clinical treatment of COVID-19. |
| format |
article |
| author |
Lihua Qu Chao Chen Tong Yin Qian Fang Zizhan Hong Rui Zhou Hongbin Tang Huifen Dong |
| author_facet |
Lihua Qu Chao Chen Tong Yin Qian Fang Zizhan Hong Rui Zhou Hongbin Tang Huifen Dong |
| author_sort |
Lihua Qu |
| title |
ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review |
| title_short |
ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review |
| title_full |
ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review |
| title_fullStr |
ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review |
| title_full_unstemmed |
ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review |
| title_sort |
ace2 and innate immunity in the regulation of sars-cov-2-induced acute lung injury: a review |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/f3eb507a47094bab8b3cde90601693e3 |
| work_keys_str_mv |
AT lihuaqu ace2andinnateimmunityintheregulationofsarscov2inducedacutelunginjuryareview AT chaochen ace2andinnateimmunityintheregulationofsarscov2inducedacutelunginjuryareview AT tongyin ace2andinnateimmunityintheregulationofsarscov2inducedacutelunginjuryareview AT qianfang ace2andinnateimmunityintheregulationofsarscov2inducedacutelunginjuryareview AT zizhanhong ace2andinnateimmunityintheregulationofsarscov2inducedacutelunginjuryareview AT ruizhou ace2andinnateimmunityintheregulationofsarscov2inducedacutelunginjuryareview AT hongbintang ace2andinnateimmunityintheregulationofsarscov2inducedacutelunginjuryareview AT huifendong ace2andinnateimmunityintheregulationofsarscov2inducedacutelunginjuryareview |
| _version_ |
1718432213318500352 |